Aurina Pharmaceuticals reported third‑quarter 2025 financial results, posting net product sales of $70.6 million, a 27% year‑over‑year increase, and total revenue of $73.5 million, up 8% from the same period last year. Cash, cash equivalents, restricted cash and investments totaled $351.8 million as of September 30, 2025.
The company raised its 2025 guidance, projecting total revenue of $275 million to $280 million and net product sales of $265 million to $270 million, compared with prior guidance of $260 million to $270 million and $250 million to $260 million, respectively. Management cited stronger‑than‑expected sales growth for LUPKYNIS, driven by increased physician adoption and inclusion in the American College of Rheumatology’s updated treatment guidelines for lupus nephritis.
Net product sales were largely driven by LUPKYNIS, which accounted for $67.8 million of the $70.6 million in product sales. License, collaboration and royalty revenue totaled $2.8 million, down from $12.3 million in Q3 2024, largely due to the absence of a $10 million milestone payment received in the prior year.
During the nine‑month period ended September 30, 2025, Aurina repurchased 12.2 million shares for $98.2 million, underscoring its commitment to returning value to shareholders.
Aurina’s strong performance is supported by LUPKYNIS’s status as the first FDA‑approved oral therapy for lupus nephritis and its recommendation as first‑line therapy in updated ACR guidelines. The company is advancing its pipeline asset aritinercept toward clinical studies for two autoimmune diseases, and a late‑2024 restructuring that cut the workforce by 45% has delivered significant operating‑expense savings. Competition for LUPKYNIS includes GSK’s Benlysta, but the company’s market position remains robust.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.